C
Cassandra G Almasri
Researcher at National Institutes of Health
Publications - 8
Citations - 83
Cassandra G Almasri is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Atopic dermatitis. The author has an hindex of 2, co-authored 2 publications receiving 30 citations.
Papers
More filters
Journal ArticleDOI
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.
Mangaiarkarasi Asokan,Joana Dias,Cuiping Liu,Anna Maximova,Keenan Ernste,Amarendra Pegu,Krisha McKee,Wei Shi,Xuejun Chen,Cassandra G Almasri,Wanwisa Promsote,David R. Ambrozak,Lucio Gama,Jianfei Hu,Daniel C. Douek,John-Paul Todd,Jeffrey D. Lifson,Slim Fourati,Rafick Pierre Sekaly,Andrew R. Crowley,Margaret E. Ackerman,Sung Hee Ko,Divya Kilam,Eli Boritz,Laura E. Liao,Katharine Best,Alan S. Perelson,John R. Mascola,Richard A. Koup +28 more
TL;DR: The studies show that the predominant mechanism of antiviral activity of HIV NAbs is through inhibition of viral entry, but that Fc function can contribute to the overall antiviralActivity, making them distinct from standard ARVs.
Journal ArticleDOI
Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.
Amarendra Pegu,Lin Xu,Megan E. DeMouth,Giulia Fabozzi,Kylie March,Cassandra G Almasri,Michael D. Cully,Keyun Wang,Eun Sung Yang,Joana Dias,Christine M. Fennessey,Jason Hataye,Ronnie Wei,Ercole Rao,Joseph P. Casazza,Wanwisa Promsote,Mangaiarkarasi Asokan,Krisha McKee,R. Schmidt,Xuejun Chen,Cuiping Liu,Wei Shi,Hui Geng,Kathryn E. Foulds,Shing Fen Kao,Amy T. Noe,Hui Li,George M. Shaw,Tongqing Zhou,Constantinos Petrovas,John Paul Todd,Brandon F. Keele,Jeffrey D. Lifson,Nicole A. Doria-Rose,Richard A. Koup,Zhi Yong Yang,Gary J. Nabel,John R. Mascola +37 more
TL;DR: In this article , trispecific neutralizing antibodies (bNAbs) were used for the treatment of HIV-1 infection in viremic SHIV-infected macaques.
Journal ArticleDOI
Anti-HIV-1 Antibodies: An Update.
TL;DR: An update is given on the current status of antibody-based anti-HIV-1 treatments comprising either receptor-targeting antibodies or broad neutralizing antibodies, and their mechanism of action and the challenges in developing them, providing insight for their development as novel clinical therapies against HIV-1 infection.
Journal ArticleDOI
Thrombin and Fibrinogen Play a Critical Role in Atopic Dermatitis Pathogenesis
Michael Sherenian,Alyssa Filuta,P. Amezcua,Brandy P. Ruff,John Kroner,Brittany Grashel,Hua He,C W Hicks,Cassandra G Almasri,Jocelyn M. Biagini,Lisa J. Martin,Joseph Palumbo,Gurjit K. Khurana Hershey +12 more
Journal ArticleDOI
Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections
Wanwisa Promsote,Lin Xu,Jason Hataye,Giulia Fabozzi,Kylie March,Cassandra G Almasri,Megan E. DeMouth,Sarah E. Lovelace,Chloe A. G. Talana,Nicole A. Doria-Rose,Krisha McKee,Sabrina H. Hait,Joseph P. Casazza,David R. Ambrozak,Jochen Beninga,Ercole Rao,Norbert Furtmann,Joerg Birkenfeld,Elizabeth McCarthy,John Paul Todd,Constantinos Petrovas,Mark Connors,Andrew Hebert,Jun-Kang Shen,Bailin Zhang,Mikhail N. Levit,Ronnie Wei,Zhi Yong Yang,Amarendra Pegu,John R. Mascola,Gary J. Nabel,Richard A. Koup +31 more
TL;DR: In this paper , a trispecific antibody (Ab), N6/αCD3-αCD28, was developed and evaluated to simultaneously activate latent HIV, increase immune activation and enhance the killing of latently-infected cells.